Minimal Change Podocytopathy with Coexistent Thin Glomerular Basement Membrane following Exposure to Semaglutide
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are FDA-approved for weight loss and are increasingly prescribed for patients with obesity and type 2 diabetes mellitus. Multiple studies have demonstrated desirable renal and cardiovascular benefits from these novel agent...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Glomerular Diseases |
| Online Access: | https://karger.com/article/doi/10.1159/000543357 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|